Bionomics Limited/fi

Neuphoria Therapeutics Inc. announced a revenue distribution of AUD $1.416 million from its participation in the former Cancer Therapeutics Cooperative Research Centre (CTx CRC).

Neuphoria Therapeutics Inc. announced its CEO, Spyridon Spyros Papapetropoulos, will transition from full-time CEO to an interim consulting role, focusing on a strategic transaction.

Neuphoria Therapeutics Inc. announced it has regained compliance with Nasdaq's listing rules after successfully holding its annual general shareholder meeting on December 12, 2025.

Neuphoria Therapeutics Inc. announced the results of its Annual Meeting, where shareholders elected two Class I directors, ratified the auditor, and approved executive compensation on an advisory basis.

Neuphoria Therapeutics Inc. has adopted a limited-duration stockholder rights plan to protect against unwanted takeovers and allow its Board to evaluate strategic alternatives.

Neuphoria Therapeutics Inc. announced its BNC210 Phase 3 trial for social anxiety disorder did not meet its primary or secondary endpoints, leading to program discontinuation.

Neuphoria Therapeutics Inc. reported a net loss for the quarter ended March 31, 2026, and is undergoing a strategic review, pausing its PTSD program.

Neuphoria Therapeutics Inc. reported a significant net loss increase, discontinued its SAD program after a Phase 3 trial failure, and initiated a strategic review amidst an unsolicited acquisition offer.

Neuphoria Therapeutics achieved a profitable quarter due to milestone payments from collaborations, particularly with Merck & Co., while continuing to advance its clinical programs.

Neuphoria Therapeutics reports its Q2 2025 results, marking its redomiciliation to the US and highlighting a significant milestone payment from Merck.

Bionomics Limited reports a net loss of $0.8 million for the quarter ended September 30, 2024, and provides an update on its clinical programs and financial position.

Neuphoria Therapeutics Inc. reports progress in its clinical pipeline for neuropsychiatric disorders, including BNC210 in Phase 3 for SAD and Phase 2b/3 for PTSD, alongside a $15 million milestone payment from Merck.

Bionomics Limited has released its Code of Business Conduct policy and filed its annual report on Form 10-K, outlining its commitment to ethical practices and providing a detailed overview of its financial and operational status.

Neuphoria Therapeutics Director David Ian Wilson was granted 8,537 Restricted Stock Units as part of the company's annual remuneration policy.

Neuphoria Therapeutics Inc. director Peter Miles Winston Davies was granted 8,537 restricted stock units as part of the company's annual remuneration policy.

Neuphoria Therapeutics Inc. Director Alan Fisher received a grant of 17,073 Restricted Stock Units as part of the company's annual remuneration policy.

Neuphoria Therapeutics Director Jane Ryan was granted 8,537 Restricted Stock Units as part of the company's annual remuneration policy, vesting by December 2026.

Lynx1 Capital Management LP and Weston Nichols acquired 639,110 shares of Neuphoria Therapeutics Inc. common stock for approximately $3.28 million.

Neuphoria Therapeutics Inc. President and CEO, Spyros Papapetropoulos, was granted 34,559 employee stock options with an exercise price of $8.27.

Leading proxy advisory firm ISS recommends Neuphoria shareholders vote for the company's director nominees, supporting the board's strategic review amidst a proxy contest.

Neuphoria Therapeutics Inc. has rejected a revised, lower acquisition bid from Lynx1 Master Fund LP, emphasizing its ongoing strategic review and urging shareholders to support its current board nominees.

Neuphoria Therapeutics Inc. issued statements to counter what it believes are deceptive claims by activist investor Lynx1 Master Fund LP, urging stockholders to support its current board nominees.

Neuphoria Therapeutics Inc. is defending its current board nominees and strategic review process against a dissident proxy contest initiated by Lynx1 Master Fund LP.

Neuphoria Therapeutics Inc. urges stockholders to vote for its director nominees to ensure stability during a critical strategic review process, following a failed Phase 3 clinical trial.

Neuphoria Therapeutics Inc. issues its definitive proxy statement for its December 12, 2025 Annual Meeting, facing a proxy contest from activist investor LYNX1 Master Fund LP and addressing key governance proposals following a significant clinical trial failure.

Lynx1 Capital Management LP and Weston Nichols, holding a 16.3% stake in Neuphoria Therapeutics, have made an all-cash or stock offer to acquire certain intellectual property assets from the company.

Lynx1 Capital Management LP has submitted a recalculated non-binding proposal to acquire Neuphoria Therapeutics Inc. for $4.75 per share in cash, adjusting for recent share dilution.

Lynx1 Capital Management plans to resubmit a revised offer to acquire Neuphoria Therapeutics Inc. after the company ceased its dilutive share issuances.

Lynx1 Capital Management has withdrawn its $5.20 per share acquisition offer for Neuphoria Therapeutics, citing 'reckless' share issuances and significant shareholder dilution.

Lynx1 Capital Management LP has proposed to acquire all outstanding shares of Neuphoria Therapeutics Inc. for $5.20 per share in cash, representing a 27% premium.

Lynx1 Capital Management LP and Weston Nichols have disclosed a 37.1% beneficial ownership stake in Neuphoria Therapeutics Inc., citing undervaluation and potential strategic engagement.

Coastlands Capital LP and affiliated entities have filed an exit statement for their beneficial ownership of Neuphoria Therapeutics Inc. common stock, no longer holding over 5% of the class.

Baslake Partners, LP, along with its investment manager Baselake Management, LLC and managing member David Paolella, has disclosed a 4.1% beneficial ownership stake in Neuphoria Therapeutics Inc.

Coastlands Capital LP and related entities have reported a 5.1% beneficial ownership stake in Neuphoria Therapeutics Inc., holding 120,000 shares.

Baslake Partners, along with its management entity and managing member, has disclosed a 9.4% beneficial ownership stake in Neuphoria Therapeutics Inc.

Shay Capital LLC and Shay Capital Holdings LLC have reported a 7.3% beneficial ownership stake in Neuphoria Therapeutics Inc.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.99% of Neuphoria Therapeutics Inc.'s common stock as of December 31, 2024.